NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers

a IHC staining yielded scores ranging from 0 to 3, which are representative of the amount of EHD1 and CD133 in lung cancer specimens. A score of 0–1 represented low expression, and 2–3 represented high expression. b The percentages of patients with high expression (black bar) and low expression of EHD1 (grey bar) were assigned according to different responses to EGFR-TKI (responder, n？=？12; nonresponder, n？=？11). Numbers near bars represent the percentage of patients for each condition. *P？<？0.05. c Mean OS of patients with high levels of EHD1 (n？=？11, OS of 26 mo) and low levels of EHD1 (n？=？12, OS of 39 mo) taking EGFR-TKI treatment. Mean PFS of patients with high levels of EHD1 (n？=？11, PFS of 11 mo) and low levels of EHD1 (n？=？12, PFS of 30 mo) taking EGFR-TKI treatment. P？=？0.049. d Patients with high CD133 expression were accompanied by increased expression of EHD1 protein. The expression levels of EHD1 were classified into two groups according to the IHC scoring: low-expression group (score 0 and 1) and high-expression group (score 2 and 3). e EHD1 expression in human lung cancer cell lines. f The correlation between EHD1 expression and IC50 of erlotinib in human lung cancer cell line